All In Biotech

Drug Trial Radar · NCT05983198

Phase I/II Study of [225Ac]Ac-PSMA-R2 in PSMA-positive Prostate Cancer, With/Without Prior 177Lu-PSMA RLT

SatisfACtion: Phase I/II, Open-label, Multi-center Study of [225Ac]Ac-PSMA-R2 in Men With mHSPC and Heavily Pre-treated PSMA-positive mCRPC, With/Without Prior 177Lu-labelled PSMA-targeted Radioligand Therapy

Last checked: Nov 19, 2026Latest source record: Sep 11, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Active, not recruiting

Status

Active, not recruiting

Enrollment

33

Actual

Start

Nov 7, 2023

Primary completion

Mar 4, 2031

Study completion Mar 4, 2031

Sponsor

Lead sponsor
Novartis PharmaceuticalsNovartis (NVS)
Sponsor type
Industry
First posted
Aug 9, 2023

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 1
Allocation
Non randomized
Model
Sequential
Masking
None
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
Male only, from 18 years, up to 100 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The purpose of this study is to learn if the study drug, \[225Ac\]Ac-PSMA-R2, is safe and tolerable, and has anti-tumor activity in treated patients.

Conditions

  • Prostate Cancer

Interventions

  • 225Ac-PSMA-R2Drug

    PSMA-R2 is a ligand coupled with 225Ac an alpha emitting radionuclide

  • 68Ga-PSMA-R2Radiation

    Kit for radiopharmaceutical preparation

  • 68Ga-PSMA-11Radiation

    Kit for radiopharmaceutical preparation

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Phase I Dose Escalation: Incidence and severity of DLTs during the DLT observation periodTime frame: Up to 6 weeks after the first 225Ac-PSMA-R2 dose administration
  2. Phase I Dose Escalation: Incidence and severity of adverse events (AEs) and serious adverse events (SAEs) by group and frequency scheduleTime frame: From date of the first administration of 225Ac-PSMA-R2 till 30 days safety follow-up, assessed up to approximately 15 months
  3. Phase I Dose Escalation: TolerabilityTime frame: Up to 6 weeks after the first 225AC-PSMA-R2 dose administration
  4. Phase ll Dose Expansion: Overall Response Rate (ORR)Time frame: From date of the first administration of 225Ac-PSMA-R2 until date of radiographic progression or date of death from any cause, whichever comes first, assessed up to approximately 15 months

Locations

9 sites in 4 countries. Site status is shown where the registry gives one.

  • Mayo Clinic Rochester

    Rochester, Minnesota

  • Novartis Investigative Site

    Darlinghurst, New South Wales, Australia

  • Novartis Investigative Site

    Montreal, Quebec, Canada

  • Novartis Investigative Site

    Clermont-Ferrand, France

  • Novartis Investigative Site

    Lyon, France

  • Novartis Investigative Site

    Nantes, France

  • Novartis Investigative Site

    Saint-Herblain, France

  • Novartis Investigative Site

    Vandœuvre-lès-Nancy, France

  • Novartis Investigative Site

    Dijon, Cote D Or, France

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.